Tech Company Financing Transactions
Waypoint Bio Funding Round
Waypoint Bio closed a $14.5 million Seed investment round on 6/28/2024. Backers included Hummingbird Ventures, Fifty Years and Recode Health Ventures.
Transaction Overview
Company Name
Announced On
6/28/2024
Transaction Type
Venture Equity
Amount
$14,500,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to further enhance its CAR T-cell therapies with efficacy against the tumor microenvironment, and later, Treg therapies for autoimmune diseases.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
180 Varick St, 6th Floor
New York, NY 10014
USA
New York, NY 10014
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
We are pioneering high throughput in vivo testing to develop novel cell therapies for solid tumors, autoimmune diseases, and beyond. Our platform uses ultra-high resolution spatial multi-omics and is powered by proprietary approaches using computer vision, cell therapy design, and pooled screening.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Xinchen Wang
Chief Scientific Officer
David Phizicky
VP - Administration
Tinsley Maier
Browse more venture capital transactions:
Prev: 6/28/2024: Feather venture capital transaction
Next: 7/1/2024: AnBogen Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs